Protocol Ledger

NCT05869903 · Phase III · ACTIVE NOT RECRUITING

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Interventional Phase III clinical trial protocol NCT05869903 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-05 Enrollment: 3,127 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05869903
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,127 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05869903
Protocol FieldVerified Registry Value
NCT IdentifierNCT05869903
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment3,127 participants (ACTUAL)
Registered Start Date2023-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05869903
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Huntington Park)Huntington Park, CAOpen Hospital Dossier ->
Velocity Clinical Research (Los Angeles)Los Angeles, CAOpen Hospital Dossier ->
Catalina Research Institute, LLCMontclair, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI